Market capitalization | $516.37m |
Enterprise Value | $273.05m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.10 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-100.97m |
Free Cash Flow (TTM) Free Cash Flow | $-94.43m |
Cash position | $344.28m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Astria Therapeutics forecast:
7 Analysts have issued a Astria Therapeutics forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -101 -101 |
60%
60%
|
EBIT (Operating Income) EBIT | -101 -101 |
60%
60%
|
Net Profit | -100 -100 |
83%
83%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Head office | United States |
CEO | Jill Milne |
Employees | 59 |
Founded | 2008 |
Website | www.astriatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.